Clinical trials of CDK inhibitors in MCL that block RB phosphorylation to regulate E2F1 mediated transactivation, such as palbociclib [20] (CDK4/6 inhibitor), showed promise alone or in combination with ibrutinib in relapsed MCL [20]. Here, CDK4 is linked to mantle cell lymphoma.